Opinion|Videos|November 6, 2024
Factors Guiding Treatment Selection in Generalized Myasthenia Gravis
Key Takeaways
- Cancer type, stage, and molecular profile are pivotal in guiding targeted therapy decisions, ensuring precision in treatment selection.
- Patient-specific factors, including age, performance status, and comorbidities, significantly influence the tailoring of treatment plans.
Panelists discuss how specific disease characteristics and individual patient factors influence their decision-making process when selecting treatments for generalized myasthenia gravis.
Advertisement
Video content above is prompted by the following:
- What disease and/or patient factors guide your choice of treatment?
Advertisement
Related to this article
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
2
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
3
Recapping the 2026 STARS Conference and the Push for Interdisciplinary Stuttering Care: Gerald Maguire, MD
4
Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
5